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Change page
Way forward is not obvious at asthma crossroads Barnes argues that using a combination inhaler (budesonide plus formoterol) as rescue therapy improves asthma control, 1 and several studies support it's use in the SMART (Symbicort (budesonide/ formoterol) maintenance and reliever therapy) regimen. 2 3 They have shown longer time to first exacerbation, reduced rate of severe exacerbations, and less inhaled corticosteroid dose, although with similar improvement in symptoms, peak flow rates, and quality of life in some studies.
However, the main concern is that all the above studies were conducted by the manufacturer (study design, data interpretation, data analysis, and publication). Three studies from the rival manufacturers of fluticasone/salmeterol have shown the opposite effect-stable dosing reducing exacerbation rate and improving symptom free days compared with the SMART regimen. 4 Secondly, in all SMART studies patients needing more than 10 inhalations were excluded.
Thirdly, there is no convincing evidence that in patients who are well controlled with stable dose inhaler therapy a change to the SMART regimen will be cost effective.
Of greater interest is the debate on once daily asthma maintenance therapy compared with twice daily regimens. 5 Certainly, asthma treatment is at a crossroads awaiting a change of direction. syed F Hussain consultant respiratory physician, Kettering General Hospital, Kettering, Northamptonshire NN16 8UZ syed.Hussain@kgh.nhs.uk Competing interests: SFH has received sponsorships for organising a CME programme, participating in conferences, and speaking from Astra Zeneca, GSK, and MSD. Here's to risk assessment I was delighted to read the editorial suggesting that we should move away from the primitive "one threshold fits all" mentality for starting antihypertensive treatment and take a view based on the overall cardiovascular risk. 1 We already do this when treating cholesterol for the purposes of primary prevention, so it is inconsistent not to use this approach for blood pressure, which is another continuous variable. The recent Joint British Societies' guidelines recognise this as the predicted cardiovascular risk rises with systolic blood pressure to 160 mm Hg, 2 yet they are not used as a tool for assessing whether to treat hypertension. This is part of the general problem that occurs when we assign arbitrary values to continuous and often fluctuating biological variables to create boundaries for disease labels. For example, bronchial hyperreactivity can change quite notably over time, and it can be very difficult to decide whether the label of asthma is appropriate. Our target driven culture encourages the use of these labels, but I think that they are often not very helpful, and I often use asthma drugs in those whom I would not label as asthmatic.
Glucose metabolism represents another such variable, and I look forward to the day when I read an editorial suggesting that we abandon the World Health Organization's criteria for diagnosing diabetes, in favour of a decision tool for the treatment of abnormal glucose metabolism based on risk. 
Misconceptions about pprs
Iheanacho argues that the Office of Fair Trading may have pinpointed some areas of improvement in the existing Pharmaceutical Price Regulation Scheme (PPRS). 1 However, its proposals for introducing a value based system of drug pricing are inherently flawed and, if implemented, would lead to a significant erosion of biopharmaceutical investment in the UK. It is not true that "other countries have long been able to design, implement, and benefit from effective methods of value based pricing." Many European countries base their pricing on international reference pricing where the UK's pricing has a central role. In Germany therapeutic reference pricing is used, which has led to a severe erosion of that country's research and development over the past decade. In Australia, which has been put forward as an example of value based pricing, the authorities have now decided to overhaul the system and drop their approaches to value based pricing.
What any serious assessment of drug pricing and reimbursement will uncover is that the real problem is in the detail of developing a system of value based pricing and the risk of replacing a system that works with an untried and poorly understood system that effectively undermines the balance between research investment and market return. The UK has traditionally been a leader in research in pharmaceuticals, and great care must be taken to ensure that it is not turned into a follower, which would undermine patients' access to new treatments.
